11 completed, 2 withdrawn, 1 suspended. 14 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 11, Withdrawn 2, Suspended 1 |
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
Follow gevokizumab: new trials by email Literature Review of gevokizumab trials Research Report on gevokizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy Gevokizumab, Signatera test - Colon Cancer | Phase 2 | Withdrawn | NSABP Foundation Inc | 2022-06-24 | 2022-11-04 | |
| The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease gevokizumab - Autoimmune Inner Ear Disease | Phase 2 | Completed | XOMA (US) LLC | 10 | 2013-08-01 | 2016-02-03 |
| Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum gevokizumab - Pyoderma Gangrenosum | Phase 2 | Completed | XOMA (US) LLC | 8 | 2013-05-01 | 2016-02-03 |
| Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand Placebo, gevokizumab - Osteoarthritis | Phase 2 | Completed | XOMA (US) LLC | 91 | 2013-05-01 | 2014-03-04 |
| Gevokizumab for Active Scleritis Gevokizumab - Scleritis | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 8 | 2013-03-01 | 2018-07-06 |
| Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand Placebo, gevokizumab - Osteoarthritis | Phase 2 | Completed | XOMA (US) LLC | 87 | 2012-07-01 | 2014-03-04 |
| Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris Placebo, gevokizumab - Acne Vulgaris | Phase 2 | Completed | XOMA (US) LLC | 127 | 2011-12-01 | 2014-03-04 |
| A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease XOMA 052 - Muckle Wells Syndrome, Autoinflammatory | Phase 1 / Phase 2 | Withdrawn | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 2010-08-27 | 2017-07-02 | |
| Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes Mellitus XOMA 052, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Completed | XOMA (US) LLC | 76 | 2010-05-01 | 2012-05-16 |
| Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes Xoma 052, Placebo - Type 1 Diabetes | Phase 2 | Completed | XOMA (US) LLC | 22 | 2010-02-01 | 2014-03-04 |
| Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy XOMA 052, Placebo - Type 2 Diabetes Mellitus | Phase 2 | Completed | XOMA (US) LLC | 421 | 2010-01-01 | 2011-10-04 |
| Effects of XOMA 052 on Insulin Production in Type 1 Diabetes XOMA 052, Placebo - Diabetes Mellitus Type 1 | Phase 2 | Completed | University of Zurich | 22 | 2009-09-01 | 2014-02-11 |
| Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis XOMA 052, Placebo - Rheumatoid Arthritis | Phase 2 | Suspended | XOMA (US) LLC | 18 | 2009-02-01 | 2015-12-29 |
| Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus XOMA 052, Placebo - Type 2 Diabetes | Phase 1 / Phase 2 | Completed | XOMA (US) LLC | 68 | 2007-07-01 | 2011-10-04 |
Diabetes Mellitus (4) · Diabetes Mellitus, Type 2 (3) · Diabetes Mellitus, Type 1 (2) · Osteoarthritis (2) · Acne Vulgaris (1) · Arthritis (1) · Arthritis, Rheumatoid (1) · Behcet Syndrome (1) · Colonic Neoplasms (1) · Cryopyrin-Associated Periodic Syndromes (1) · Hearing Loss, Sudden (1) · Labyrinth Diseases (1) · Meniere Disease (1) · Pyoderma Gangrenosum (1) · Scleritis (1)
XOMA (US) LLC (10) · NSABP Foundation Inc (1) · National Eye Institute (NEI) (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · University of Zurich (1)
United States (11) · Switzerland (2) · Mexico (1)
Alan Solinger, M.D. (1) · Hatice N Sen, M.D. (1) · Marc Donath, MD (1) · Marc Donath, Prof. (1) · Norman Wolmark, MD (1) · Pedro Urquilla, MD (1)
R33DC011827 (1)